시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 BCL-2 억제제 시장 보고서(2025년)
BCL-2 Inhibitors Global Market Report 2025
상품코드 : 1716922
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,253,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,039,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,824,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

BCL-2 억제제 시장 규모는 향후 수년간 급성장이 전망될 예정입니다. 이 기간에 예상되는 주요 동향으로는 내성 표적 전략의 개발, 베네토크락스의 세계 개발의 강화, 프리시전 종양의 진전, 약물전달 시스템의 개선, 제약 기업 간의 전략적 제휴 등이 있습니다.

혈액암의 유병률 증가는 향후 BCL-2 억제제 시장의 성장을 견인할 것으로 예측됩니다. BCL-2 억제제는 암세포의 아폽토시스를 회복시키는 것으로 백혈병이나 림프종 등의 치료 성적을 향상시켜, 혈액암의 치료에 중요한 역할을 하고 있습니다. 예를 들어, 2022년 8월, 모든 유형의 혈액암 퇴치에 중점을 둔 영국 기반 커뮤니티인 Blood Cancer UK는 혈액암이 영국에서 다섯 번째로 흔한 암이며, 매년 41,000건 이상의 새로운 사례가 진단되고 약 25만 명이 이 질환을 앓고 있다고 보고했습니다.

BCL-2 억제제 시장 주요 기업은 선택적 BCL-2 억제제와 같은 암세포를 보다 효과적으로 표적화하고 표적외 영향을 경감하는 혁신적인 치료법의 개발에 주력하고 있습니다. 선택적 BCL-2 억제제는 세포 자멸사(세포 사멸)를 방지하여 세포 생존을 조절하는 B세포 림프종 2(BCL-2) 단백질을 특이적으로 표적하여 억제하는 약물입니다. 예를 들어, 2024년 5월 저분자 종양학 신약 개발에 주력하는 미국 회사인 Eilean Therapeutics LLC는 급성 골수성 백혈병(AML) 및 만성 림프구성 백혈병(CLL) 등 혈액 악성 종양 치료를 목표로 하는 선택적 BCL-2 억제제인 에일토클락스의 임상시험을 시작했습니다. 호주 인간연구윤리위원회의 승인을 받은 이 임상 1상 시험은 일레토클락스의 안전성과 효과를 평가하기 위해 고안되었습니다. 전임상 검사에서 베네토크락스 등 기존 치료와 비교하여 안전성이 높고, 비악성 면역세포에 대한 영향이 적은 것이 시사되고 있어 외래 치료가 가능해져 환자의 내약성이 향상될 가능성이 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

KTH
영문 목차

영문목차

BCL-2 inhibitors are medications that target the BCL-2 protein, which helps cancer cells evade apoptosis, or programmed cell death. By blocking this protein, these drugs encourage the death of cancer cells, particularly in cancers such as leukemia and lymphoma, where BCL-2 is overexpressed.

The main types of BCL-2 inhibitors include combination therapy and monotherapy. Combination therapy involves using multiple drugs to enhance treatment effectiveness, improve outcomes, and reduce resistance in blood cancers. These inhibitors are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and other channels for various applications, including chronic lymphocytic leukemia, acute myeloid leukemia, and multiple myeloma. The key end users of these therapies include hospitals, ambulatory surgical centers, and pharmacies.

The BCL-2 inhibitors market research report is one of a series of new reports from The Business Research Company that provides BCL-2 inhibitors market statistics, including BCL-2 inhibitors industry global market size, regional shares, competitors with a BCL-2 inhibitors market share, detailed BCL-2 inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the BCL-2 inhibitors industry. This BCL-2 inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The BCL-2 inhibitors market size has grown rapidly in recent years. It will grow from $2.10 billion in 2024 to $2.47 billion in 2025 at a compound annual growth rate (CAGR) of 17.6%. The growth during the historic period can be attributed to several factors, including a focus on minimizing chemotherapy side effects, the rising prevalence of chronic diseases, and increased access to healthcare in emerging markets. Additionally, the emergence of dual-targeted therapies, a rise in personalized cancer treatments, and growing interest in maintenance therapies have contributed to this growth.

The BCL-2 inhibitors market size is expected to see rapid growth in the next few years. It will grow to $4.67 billion in 2029 at a compound annual growth rate (CAGR) of 17.2%. The growth during the forecast period can be attributed to the increasing adoption of immuno-oncology therapies, a greater focus on combination therapies, and the expansion of healthcare infrastructure in developing regions. Key trends expected during this period include the development of resistance-targeting strategies, enhanced global market penetration of Venetoclax, advancements in precision oncology, improvements in drug delivery systems, and strategic collaborations between pharmaceutical companies.

The increasing prevalence of blood cancers is expected to drive the growth of the BCL-2 inhibitors market in the future. Blood cancers are cancers that affect the blood, bone marrow, or lymphatic system, disrupting normal blood cell production and function. The rise in blood cancer cases can be attributed to factors such as aging populations, advancements in diagnostic techniques, and lifestyle changes, all contributing to higher detection rates globally. BCL-2 inhibitors play a crucial role in treating blood cancers by restoring apoptosis in cancer cells, thereby improving treatment outcomes for conditions such as leukemia and lymphoma. For example, in August 2022, Blood Cancer UK, a UK-based community focused on combating all types of blood cancer, reported that blood cancer is the fifth most common cancer in the UK, with over 41,000 new cases diagnosed annually and approximately 250,000 people living with the condition. As a result, the increasing prevalence of blood cancers is fueling the growth of the BCL-2 inhibitors market.

Key companies in the BCL-2 inhibitors market are concentrating on developing innovative treatments, such as selective BCL-2 inhibitors, to more effectively target cancer cells and reduce off-target effects. A selective BCL-2 inhibitor is a drug that specifically targets and inhibits the B-cell lymphoma 2 (BCL-2) protein, which helps regulate cell survival by preventing apoptosis (cell death). For example, in May 2024, Eilean Therapeutics LLC, a US-based company focused on small molecule oncology drug discovery, initiated a clinical trial for eiletoclax, a selective BCL-2 inhibitor aimed at treating hematological malignancies such as acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). This Phase 1 clinical trial, approved by the Australian Human Research Ethics Committee, is designed to assess the safety and effectiveness of eiletoclax. Preclinical studies suggest that it offers a better safety profile compared to existing therapies such as venetoclax, with less impact on non-malignant immune cells, potentially enabling outpatient treatment and improving patient tolerability.

In October 2023, Ascentage Pharma, a biopharmaceutical company based in China, entered into a collaboration with AstraZeneca. The goal of this partnership is to conduct a registrational Phase III study to assess the efficacy and safety of the Bcl-2 inhibitor lisaftoclax in combination with the BTK inhibitor acalabrutinib for treatment-naive patients with first-line chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). AstraZeneca, a pharmaceutical company based in the UK, specializes in orally administered small-molecule Bcl-2 selective inhibitors.

Major players in the BCL-2 inhibitors market are Roche Holding AG, Merck & Co., AbbVie Inc., Bristol-Myers Squibb, AstraZeneca PLC, Novartis AG, Eli Lilly and Co, Amgen Inc., MilliporeSigma, Laboratoires Servier, Ipsen Pharma, BeiGene Ltd., Bio-Techne Corp., Abcam plc, InnoCare Pharma, Ascentage Pharma Group Inc, Biorbyt Ltd., Zentalis Pharmaceuticals, Santa Cruz Biotechnology Inc., Guangzhou Lupeng Pharmaceutical Company Ltd., Eilean Therapeutics LLC.

North America was the largest region in the BCL-2 inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in BCL-2 inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the BCL-2 inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The BCL-2 inhibitors market consists of sales of products including chemical structure, BH3 mimetics, oral tablets, injectable solutions, and lipophilicity and selectivity components. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

BCL-2 Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bcl-2 inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for bcl-2 inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bcl-2 inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. BCL-2 Inhibitors Market Characteristics

3. BCL-2 Inhibitors Market Trends And Strategies

4. BCL-2 Inhibitors Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global BCL-2 Inhibitors Growth Analysis And Strategic Analysis Framework

6. BCL-2 Inhibitors Market Segmentation

7. BCL-2 Inhibitors Market Regional And Country Analysis

8. Asia-Pacific BCL-2 Inhibitors Market

9. China BCL-2 Inhibitors Market

10. India BCL-2 Inhibitors Market

11. Japan BCL-2 Inhibitors Market

12. Australia BCL-2 Inhibitors Market

13. Indonesia BCL-2 Inhibitors Market

14. South Korea BCL-2 Inhibitors Market

15. Western Europe BCL-2 Inhibitors Market

16. UK BCL-2 Inhibitors Market

17. Germany BCL-2 Inhibitors Market

18. France BCL-2 Inhibitors Market

19. Italy BCL-2 Inhibitors Market

20. Spain BCL-2 Inhibitors Market

21. Eastern Europe BCL-2 Inhibitors Market

22. Russia BCL-2 Inhibitors Market

23. North America BCL-2 Inhibitors Market

24. USA BCL-2 Inhibitors Market

25. Canada BCL-2 Inhibitors Market

26. South America BCL-2 Inhibitors Market

27. Brazil BCL-2 Inhibitors Market

28. Middle East BCL-2 Inhibitors Market

29. Africa BCL-2 Inhibitors Market

30. BCL-2 Inhibitors Market Competitive Landscape And Company Profiles

31. BCL-2 Inhibitors Market Other Major And Innovative Companies

32. Global BCL-2 Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The BCL-2 Inhibitors Market

34. Recent Developments In The BCL-2 Inhibitors Market

35. BCL-2 Inhibitors Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기